Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Bei WangRong DengStefanie HennigTanja Badovinac CrnjevicMonika KaewphlukMatts KågedalAngelica L QuartinoSandhya GirishChunze LiWhitney P KirschbrownPublished in: Cancer chemotherapy and pharmacology (2021)
The approved PH FDC SC dose [loading: 1200/600 mg pertuzumab/trastuzumab (15 mL); maintenance: 600 mg pertuzumab/trastuzumab (10 mL) and 2000 U/mL recombinant human hyaluronidase every 3 weeks] provides a positive benefit-risk profile with comparable efficacy and safety to intravenous pertuzumab plus trastuzumab.